112 results about "Angiopathy" patented technology

The invention discloses a post-stroke depression risk prediction system based on cerebral small vascular diseases and inflammatory markers, and relates to the technical field of computer-aided engineering, the post-stroke depression risk prediction system comprises: a data acquisition module acquires CSVD image data, serum inflammatory markers and clinical baseline information; the data preprocessing module processes image denoising registration, fills up marker missing values and encodes clinical information; the CSVD feature extraction module extracts image omics features and quantifies severity; the inflammation marker module calculates statistical characteristics and inflammation intensity; the multi-dimensional fusion module integrates features and eliminates redundancy; the risk prediction module is trained by using an improved attention CNN-LSTM model; the result output module visualizes risk and intervention suggestions; the model dynamic optimization module updates parameters by incremental learning. According to the method, multi-source key data are integrated, the prediction accuracy and generalization ability are improved, clinical interpretation and dynamic adaptability are achieved, early recognition of post-stroke depression is assisted, and patient prognosis is improved.

Disclosed are methods, systems, and a device for automated interpretation of cardiac magnetic resonance imaging. A method includes acquiring a sequence of radiographic images of a heart, including at least one of: a cine MRI, a late gadolinium enhancement, a T1 mapping, a T2 mapping, a perfusion imaging, a flow quantification, a dark blood imaging, a real-time imaging, a magnetic resonance spectroscopy, or a parametric mapping sequence. Further, the method processes the sequence of radiographic images using one or more machine learning models. Additionally, the method generates a diagnostic prediction using the machine learning models. The diagnostic prediction is a screening prediction of a cardiac anatomy, a diagnostic suggestion of a cardiovascular condition, a quantitative assessment of a cardiac function parameter, a structured radiographic report, a natural language summary, or a diagnostic rationale. A diagnostic prediction is output to an electronic system.

The present invention relates to compounds of formula (I), and stereoisomers, tautomers, N- oxides, and pharmaceutically acceptable salts thereof that are useful for modulating, preferably inhibiting three-prime repair exonuclease (TREX1). The present invention further relates to compounds of formula (I) for use as a medicament and to pharmaceutical compositions comprising said compounds. Further, the present invention relates to compounds of formula (I) and pharmaceutical compositions comprising said compounds for use in the treatment of cancer, such as breast, small cell lung cancer and colorectal cancer, in particular cancers with chromosomal instability, TREX1-mediated autoimmune diseases, inflammatory myocarditis, Aicardi-Goutières syndrome (AGS), familial chilblain lupus (FCL), systemic lupus erythematosus (SLE) and retinal vasculopathy with cerebral leukodystrophy (RVCL).

Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD, NASH, or MASH, or drug induced liver injury (DILI).

Compositions and methods of use for modulating APOE mediated signaling are provided. For example, immunomodulatory agents are provided that reduce APOE expression, ligand binding, crosslinking, APOE mediated signaling, or a combination thereof. In another embodiment, immunomodulatory agents are provided that enhance or promote APOE expression, ligand binding, crosslinking, APOE mediated signaling, or a combination thereof. Such agents can be used to modulate an immune response in a subject in need thereof, wherein the subject has a neurodegenerative disease, such as Alzheimer's disease or cerebral amyloid angiopathy.

The invention relates to the technical field of cardiovascular disease health risk assessment and management, and discloses a cardiovascular patient group health assessment system based on diet and individual characteristics, which comprises a data acquisition module, an analysis and prediction module and a health assessment module. According to the cardiovascular patient group health assessment system based on diet and individual characteristics, a data acquisition module acquires a user data set, a data preprocessing unit identifies the user data set, a risk proportion unit calculates a disease risk ratio Hbfx, and a variable prediction unit calculates a disease prediction data set Fbyc; the health assessment module calculates a comprehensive influence data set Zhyx and comprehensively assesses the influence of significant variables of a user on CVD risks, analysis and assessment are more comprehensive and highly targeted, the health assessment module compares a reference data set according to the comprehensive influence data set Zhyx and judges and assesses corresponding scores, and the effect of early intervention and treatment of cardiovascular diseases is better.

This invention relates to a method and system for cardiovascular disease risk assessment based on machine learning models. By utilizing machine learning models to focus on predicting the risk of heart failure, it accurately distinguishes between healthy individuals and those with cardiovascular disease, emphasizing the differentiation of heart failure and other common cardiovascular diseases, and deeply exploring diagnostic indicators, thus opening new avenues for cardiovascular diagnosis and treatment. It hierarchically utilizes features closely related to blood cells, blood lipids, and blood glucose, and constructs predictive models using multiple machine learning models, laying a solid foundation for further in-depth research. This invention fully utilizes diagnostic indicators and multiple machine learning models, making full use of the predictive results and differentiated characteristics of different machine learning models to achieve efficient and accurate 5-category risk assessment.

Disclosed are novel compounds that are antagonists of the human GPR39 protein. Disclosed are pharmaceutical compositions of antagonists of the human GPR39 protein and methods of use. In particular, disclosed herein are methods of using the antagonists to treat diseases or conditions, including cardiovascular conditions, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, blood disorders, neurological disorders, and respiratory diseases.

The invention discloses a nattokinase product for preventing and / or treating atherosclerosis and application of the nattokinase product. Cardiovascular diseases become the primary reason of human death, and the vascular plaque problem caused by atherosclerosis is always a difficult problem to be solved urgently. Blood vessel stenosis caused by plaques is a main cause of cerebral arterial thrombosis, and traditional medicines and operations face the problems of low compliance, side effect risk, indication limitation and the like. The invention provides nattokinase or a product thereof for high-risk groups with cardiovascular diseases, and the nattokinase or the product thereof is preferably in a non-drug form. As a precise nutrition intervention means, nattokinase is effective in plaque progress inhibition, unique in effect, safe to eat, convenient, easy to implement and wide in applicable crowd. The invention provides a new thought and method for management of vascular plaques and prevention and treatment of cardiovascular diseases.

The invention provides an application of Exifenone in preparation of a medicine for treating diabetic retinopathy, the Exifenone can be combined near a K412 lactic acid modification site of HDAC1, so that the lactic acid modification of the K412 site of the HDAC1 is specifically inhibited, the deacetylation activity of the HDAC1 to H3K56 is enhanced, the transcriptional activation of VEGFA (vascular endothelial growth factor A) mediated by H3K56ac and pathological angiogenesis are inhibited, and the effect of treating diabetic retinopathy is achieved. Further, vascular pathological injury caused by diabetic retinopathy is improved. The application provides a new target and a candidate drug for clinical treatment of diabetic retinopathy. The research result of the application provides experimental evidence for the epoxybenzophenone to be used for clinical specific treatment of diabetic retinopathy.

The application belongs to the technical field of biomedicine, and particularly relates to a construction system of a cerebral amyloid angiopathy recognition model, a storage medium and a kit. Based on plasma proteomic data of cerebral amyloid angiopathy patients and normal old controls, six key protein markers closely related to cerebral amyloid angiopathy are screened out. The application also provides a model for recognizing cerebral amyloid angiopathy based on a combination of six plasma protein biomarkers. The model shows excellent performance in multiple independent data sets, can accurately distinguish cerebral amyloid angiopathy patients from normal old controls, and further distinguish cerebral amyloid angiopathy patients with high-risk cerebral hemorrhage risk from those with low-risk cerebral hemorrhage risk. The application provides a new tool for early diagnosis and hemorrhage risk assessment of cerebral amyloid angiopathy.

The invention relates to the technical field of compression hemostasis, and particularly discloses a cardiovascular patient postoperative compression hemostasis auxiliary device which comprises a compression hemostasis body and a winding mechanism, and the winding mechanism is arranged on one side of a compression cover to wind a first binding belt and a second binding belt; the detection mechanism is arranged in the winding mechanism and is used for monitoring the puncture point of the patient; the salt adding mechanism is arranged in the sealing cover and is used for adding salt into the compressed salt bag. A rolling column on the second binding belt is inserted into the rolling mechanism, the first binding belt and the second binding belt are gradually rolled through the rolling mechanism, so that pressure is applied to the pressing cover to press a puncture point, and meanwhile whether the pressed puncture point bleeding or not can be detected through the detection mechanism; whether the patient is bleeding or not can be displayed to medical staff through the test strip.

Provided are compositions comprising an oligonucleotide that targets Angiopoietin-like 4 (ANGPTL4). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating a metabolic or cardiovascular disorder by providing an oligonucleotide that targets ANGPTL4 to a subject in need thereof.

The present application belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating cerebrovascular disease and a preparation method thereof. The traditional Chinese medicine composition for treating cerebrovascular disease comprises the following raw materials in parts by weight: 19-24 parts of chuanxiong, 15-20 parts of gastrodia, 8-14 parts of kudzu vine tea, 11-17 parts of San Ye Qing Teng, 3-9 parts of hibiscus flower, 7-12 parts of polygala, and 2-5 parts of licorice. The chuanxiong in the composition has the effects of activating blood and regulating qi, and the gastrodia has the effects of calming wind and stopping convulsion, and both of them are used as monarch drugs. The kudzu vine tea and San Ye Qing Teng are used as minister drugs, the kudzu vine tea has the effect of resolving and dredging collaterals, and the San Ye Qing Teng has the effect of dispelling wind and relieving pain. The hibiscus flower and polygala are both used as auxiliary drugs, and the licorice is used as a guide drug. The licorice can not only harmonize all drugs, but also warm the center and promote drug absorption. The traditional Chinese medicine composition has the effects of activating blood and resolving stasis, dredging collaterals and relieving pain, and soothing the nerves and helping sleep. The composition has good therapeutic effects on stroke and apoplexy.

Provided for are compositions and methods for treating amyloid related imaging abnormalities (ARIA) with selective Janus kinase (JAK) inhibitors in Alzheimer's disease (AD) patients or patients with other with neurodegenerative disease or cerebral amyloid angiopathy-related inflammation (CAAri) undergoing anti-amyloid therapy, including anti- amyloid antibody therapies. Particularly useful are JAK inhibitors selective against JAK1 and tyrosine kinase 2 (TYK2).

The invention provides a construction method of a hypertension-cerebral hypoperfusion composite cerebral small vascular disease rat model. The construction method comprises the steps of experimental animal and grouping, hypertension model induction, cerebral hypoperfusion model induction and model evaluation system. According to the model, hereditary hypertension is replaced by 'L-NAME-induced drug-induced hypertension', and the model is combined with bilateral carotid artery occlusion surgery, so that clinical common hypertension and cerebral hypoperfusion dual pathological processes are successfully simulated. Compared with an SHR model, drug-induced hypertension is adopted to replace hereditary hypertension, and the method has the remarkable advantages in the aspects of period-cost-controllability-flux, 1, the modeling period is shortened to 8 weeks, and about 2 / 3 of time is saved; (2) the cost of a single animal is less than 1 / 3 of that of SHR, and the method is suitable for large-sample and multi-batch research; (3) the dosage of the L-NAME is adjustable, and the two-way intervention research of'hypertension driving 'and'blood pressure normalization' is supported; background data of the SD rats are complete and sufficient in supply, and multi-center repeated experiments are facilitated.

This invention provides a deep learning-based intelligent analysis method for cardiovascular medical images, comprising the following steps: S1, heterogeneous data fusion and acquisition of multimodal medical images and physiological signals; S2, intelligent extraction and quantitative analysis of vascular structural features based on deep learning; S3, hemodynamic parameter modeling and risk region segmentation based on fused structural features; S4, texture feature mining and intelligent identification of lesion types in high-risk areas; S5, cardiovascular disease risk stratification prediction based on multi-dimensional feature fusion; S6, federated learning optimization and closed-loop update of the model. This invention's deep learning-based intelligent analysis method for cardiovascular medical images achieves, for the first time, heterogeneous fusion of medical images, millimeter-wave radar-PPG physiological signals, and clinical molecular data, and achieves precise spatiotemporal alignment through GPS-controlled crystal oscillators, overcoming the limitations of single image analysis and providing a more comprehensive feature foundation for subsequent feature extraction and risk prediction.

The invention discloses a traditional Chinese medicine preparation for preventing postoperative vascular stenosis and occlusion and a preparation method thereof, and relates to the technical field of traditional Chinese medicines. The traditional Chinese medicine preparation for preventing postoperative vascular stenosis and occlusion is prepared from a multi-layer assembled amphiphilic polymer, a traditional Chinese medicine compound extract and curcumin, the multi-layer assembled amphiphilic polymer is used as a carrier, curcumin and a traditional Chinese medicine compound extract are effectively loaded in an encapsulation and adsorption mode, the drug loading capacity is improved, the drug concentration of a drug at a vascular focus part can be remarkably improved in a long-circulation, targeting and pH response release precise delivery mode, the bioavailability of the drug is improved, and the bioavailability of the drug is improved. Meanwhile, the precise delivery mode can also reduce the distribution of the medicine in normal tissues, so that the toxic and side effects are reduced, and the treatment safety is improved.

Provided herein are methods of treating, preventing, and managing metabolic or cardiovascular disorders and methods of reducing cardiovascular risk with FGF21 protein variants, including Fc-FGF21 variant fusion proteins.

A chemically modified polynucleotide encoding a fusion protein, wherein the chemically modified polynucleotide comprises a sequence of SEQ ID NO: 701 is claimed wherein the fusion comprises a Cas9 nickase and and deaminase, such as an adenosine deamnase TadA. and which further comprises a protospacer found on a gene encoding Angiopoietin-like 3 protein (ANGPTL3). The chemical modifications may include phosphorothioate linkages and 2'-O-methyl modfied nucleosides. Use of such fusions in treating cardiovascular conditions is further claimed. [Figure 3]

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain H-APPAMP compounds (referred to herein as “H-APPAMP compounds”) that, inter alia, inhibit cyclin-dependent protein kinases (CDKs), especially CDK12 and / or CDK13, and are selective, for example, for CDK12 and / or CDK13 as compared to CDK7. In addition to selectively inhibiting CDK12 and / or CDK13, the compounds also act as selective Cyclin K degraders thereby removing the key signaling mechanism required for CDK12 and / or CDK13 activation; this confers additional cellular potency and selectivity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CDK, especially CDK12 and / or CDK13; and to treat disorders including: disorders that are associated with CDK, especially CDK12 and / or CDK13; disorders that result from an inappropriate activity of a CDK, especially CDK12 and / or CDK13; disorders that are associated with CDK mutation, especially CDK12 and / or CDK13 mutation; disorders that are associated with CDK overexpression, especially CDK12 and / or CDK13 overexpression; disorders that are associated with upstream pathway activation of CDK, especially CDK12 and / or CDK13; disorders that are ameliorated by the inhibition of CDK, especially CDK12 and / or CDK13; proliferative disorders; cancer; viral infections (including HIV); neurodegenerative disorders (including Alzheimer's disease and Parkinson's disease); ischaemia; renal diseases; cardiovascular disorders (including atherosclerosis); autoimmune disorders (including rheumatoid arthritis); and disorders caused by dysfunction of translation in cells (including muscular dystrophy). Optionally, the treatment further comprises treatment (e.g., simultaneous or sequential treatment) with a further active agent which is, e.g., an aromatase inhibitor, an anti estrogen, an anti-androgen, a Her2 blocker, a cytotoxic chemotherapeutic agent, an agent stimulating the immune system, a checkpoint inhibitor, a DNA repair inhibitor, etc.

The present invention provides siRNA, peptide oligonucleotide drugs, and their applications for suppressing the expression of the amyloid precursor protein (APP) gene in human cells. The siRNA exhibits potent activity in inhibiting APP expression. Through appropriate modifications, its ability to silence the target is enhanced while reducing off-target activity. The described siRNA and its conjugates hold promise for clinical application in the prevention and treatment of diseases associated with the APP target, including cerebral amyloid angiopathy (CAA), early-onset familial Alzheimer's disease (EOFAD), or Alzheimer's disease (AD).

Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD or NASH, or drug induced liver injury (DILI).

Compositions and methods of use for modulating APOE mediated signaling are provided. For example, immunomodulatory agents are provided that reduce APOE expression, ligand binding, crosslinking, APOE mediated signaling, or a combination thereof. In another embodiment, immunomodulatory agents are provided that enhance or promote APOE expression, ligand binding, crosslinking, APOE mediated signaling, or a combination thereof. Such agents can be used to modulate an immune response in a subject in need thereof, wherein the subject has a neurodegenerative disease, such as Alzheimer's disease or cerebral amyloid angiopathy.

The application relates to a plasma waste liquid color analysis method, a system, a readable storage medium and equipment, the method comprising the following steps: collecting an image of a transparent container containing plasma waste liquid to obtain an initial image; wherein the plasma waste liquid is obtained after plasma is filtered by adopting a double filtration plasma replacement method; the initial image is preprocessed and color space conversion is performed to obtain an image to be analyzed; a color feature vector is extracted from the image to be analyzed; and the color feature vector is input into a pre-trained classification model to obtain a classification result; through computer vision technology, non-invasive and rapid identification of the nature of DFPP waste liquid is realized, objective and convenient reference indexes are provided for clinical doctors to adjust treatment parameters, evaluate the metabolic state of patients and the risk of cardiovascular diseases, detection cost is effectively reduced, and diagnosis and treatment efficiency is improved.

The present application relates to the use of vascular BACE1 as a therapeutic target for diseases related to cerebral small vessel injury. Specifically, it relates to the use of a substance that reduces the expression level of the beta-secretase (BACE1) gene and / or an inhibitor of the enzymatic activity of BACE1 protein in the preparation of a drug for treating or alleviating cerebrovascular disease, wherein the disease related to cerebral small vessel injury is preferably Alzheimer's disease, amyloid cerebral small vessel disease, and vascular dementia. The inventors have found that an increase in the content of BACE1 can cleave the tight junction protein Occludin, resulting in the degradation and loss of tight junction proteins between vascular endothelial cells, causing the structure and function of the blood-brain barrier to be damaged, ultimately leading to cerebral microbleeds and cognitive dysfunction and other pathological phenotypes of diseases related to cerebral small vessel injury; inhibition of the enzymatic activity of BACE1 can improve these pathological phenotypes of diseases related to cerebral small vessel injury.

The application relates to the technical field of cardiovascular disease diagnosis and treatment and artificial intelligence, and discloses a cardiovascular disease diagnosis and treatment scheme optimization system based on architecture, which comprises an original data preprocessing module, which is used for collecting and standardizing time series monitoring data and static data of medical history texts, adopts an improved and normalized algorithm, utilizes model structured text data, and outputs standardized patient feature data; and an improved logic analysis module, which is used for receiving the standardized patient feature data, optimizing the architecture by introducing a sparse attention mechanism, and performing time series correlation analysis, pathological feature mapping and individual difference modeling. The improved logic analysis module is used for introducing the sparse attention mechanism, deeply mining time series correlation and implicit pathological logic coupling relationships in complex time series monitoring data, generating a high-dimensional patient state feature vector, and solving the problem that traditional methods are shallow in analysis and cannot accurately identify individualized pathological states.

The invention relates to a cardiovascular disease risk cycle assessment method based on big data, and the method is characterized in that the method comprises the steps: obtaining a preliminary diagnosis result through correlation analysis and a support vector machine model according to the basic information and symptom performance of a patient; according to comprehensive information such as electrocardiograms, echocardiograms, blood examination and CT examination, the cardiovascular conditions are classified through a correlation analysis algorithm and a Bayesian classifier. Physiological indexes such as electrocardio, blood pressure and blood fat are monitored regularly, a physiological change period is obtained, and influences of factors such as diet, exercise and emotion on the physiological change period are analyzed. Based on the electrocardiogram period, the blood pressure fluctuation period and the blood fat change period, an ARIMA model is established to predict the lesion period. And further fusing surgical treatment, drug treatment, lifestyle adjustment and psychological treatment schemes, and constructing a recurrence probability and recurrence cycle prediction model by combining basic information and physiological change cycle of the patient. And finally, dynamically adjusting a monitoring period according to a prediction result, and providing a monitoring result and personalized adjustment suggestions for a doctor or a patient through a medical system, thereby realizing periodic and dynamic assessment and management of cardiovascular disease risks.

Disclosed herein are compounds suitable for use in the treatment of disorders, e.g., diabetic disorder, a dyslipidemia disorder, a cardiovascular disorder, an inflammatory disorder, a hepatic disorder, cancer, or obesity or co-morbidities thereof. Also disclosed are compositions containing one or more of the compounds and uses of the compounds in the treatment of disorders in a subject.

The invention relates to compounds of Formula (I), or pharmaceutically acceptable salts thereof; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may be useful as therapeutic and / or preventative agents to treat diseases that involve abnormal amino acid metabolism, amino acid transport and / or amino acid level, cardiovascular disorders, renal disorders, or metabolic diseases, such as phenylketonuria, NASH, NAFLD, heart failure, chronic kidney disease, and related disorders.